贝伐珠单抗联合XELOX方案治疗转移性结直肠癌的效果  

Effect of Bevacizumab combined with XELOX scheme in teatment of metastatic coloretal cancer

作　　者：何盛泉[1] 骆影超 赖家骏[1] 曾德强[1] 张涛[1] 

机构地区：[1]广东省韶关市粤北人民医院胃肠外科,广东韶关512026

出　　处：《中国当代医药》2017年第8期72-74,共3页China Modern Medicine

摘　　要：目的比较贝伐珠单抗联合XELOX(卡培他滨联合奥沙利铂)方案与单纯使用XELOX方案化疗治疗转移性结直肠癌的效果、安全性和患者生存率。方法收集我院2013年1月~2014年6月收治的55例转移性结直肠癌患者,随机分为观察组(26例)和对照组(29例),观察组予贝伐珠单抗联合XELOX方案化疗,对照组予XELOX方案化疗,比较两组的疗效、不良反应发生率以及生存率。结果观察组有效率为26.92%,高于对照组的10.34%,差异有统计学意义(P<0.01)。两组患者的不良反应发生率、疾病控制率、生存率差异无统计学意义(P>0.05)。结论贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌是安全的,能够提高治疗效果。Objective To compare the clinical effect,safety and survival rate between Bevacizumab combined with XELOX（Capecitabine combined with Oxaliplatin） regimen and only XELOX regimen in treatment of metastatic coloretal cancer.Methods 55 patients with metastatic coloretal cancer treated in our hospital from January 2013 to June 2014 were selected and randomly divided into observation group（26 cases） and control group（29 cases）.The observation group was treated with Bevacizumab combined with XELOX regimen while the control group with XELOX regimen only.The clinical effect,incidence rate of adverse reaction and survival rate between two groups were compared.Results The effective rate in observation group（26.92%） was higher than that of 10.34% in control group,and the difference was statistically significant（P 〈0.01）.There was no statistic difference in incidence rate of adverse reaction,disease control rate and survival rate（P〉0.05）.Conclusion Bevacizumab combined with XELOX regimen is safe,which can increase the clinical efficacy treating metastatic coloretal cancer.

关 键 词：转移性结直肠癌 贝伐珠单抗 卡培他滨联合奥沙利铂 

分 类 号：R735.3[医药卫生—肿瘤]